George Freeman welcomes publication of the Accelerated Access Review which he launched when he was Life Sciences Minister. The review sets out a new model for the NHS to make use of its it genetic and data leadership to get quicker access and discounted prices; which will enable patients with rare diseases gain to access innovative medicines. He calls on the PM to encourage the National Institute for Health and Care Excellence and NHS England to implement it speedily.
Every year, hundreds of people are diagnosed with, suffer and usually die prematurely from rare diseases such as cystic fibrosis and rare cancers, for which there has been no treatment, or for which the latest drugs are prohibitively expensive. This week sees the final report of our accelerated access review, which sets out a new model for the NHS to use its genetic and data leadership to get quicker access and discounted prices. Will the Prime Minister join me in welcoming the review, which is strongly supported by patients, charities and the life sciences sector, and in encouraging the National Institute for Health and Care Excellence and NHS England to implement it speedily?
I certainly join my hon. Friend in welcoming the publication of the review. This is important in enabling patients to get quicker access to drugs and treatments. The United Kingdom has established a leading role in life sciences, and I pay tribute to my hon. Friend for the role he has played in that. I know that the Department of Health will be looking very closely at the report’s specific recommendations, recognising that where we can take opportunities through the national health service to encourage the development of new drugs to benefit patients, we should do so.